改良二联方案与标准四联方案治疗幽门螺杆菌感染临床对照研究

Clinical comparison between improved double regimen and standard quadruple regimen for Helicobacter pylori

目的探讨伏诺拉生联合阿莫西林7d疗法根除幽门螺杆菌(Hp)的临床应用价值。方法收集2022年3月至2022年11月遵义医科大学第五附属(珠海)医院消化内科收治的100例Hp感染的患者临床资料,分为研究组(伏诺拉生+阿莫西林)和对照组(标准四联疗法),每组各50例。统计分析两组患者的Hp根治情况、临床症状缓解情况、不良反应发生情况及成本-效果分析。结果研究组根治率为94%,对照组为88%,差异无统计学意义(P>0.05);研究组患者临床症状缓解率为84%,显著高于对照组的62%,差异有统计学意义(P<0.05);研究组不良反应发生率为12%,显著低于对照组的54%,差异有统计学意义(P<0.05);研究组总费用为143.02元,对照组总费用384.41元,研究组成本低于对照组。结论伏诺拉生联合阿莫西林7 d疗法可达到标准四联的根除率,临床症状缓解率高,不良反应率低,成本低,值得推广。

Objective To study clinical application value of Vonoprazan combined with amoxicillin for 7 day regimen of Helicobacter pylori eradication.Methods The clinical data of 100 cases of Hp infection admitted to the Gastroenterology Department of the Fifth Affiliated(Zhuhai)Hospital of Zunyi Medical University were divided into study group(Vonoprazan+amoxicillin)and control group(Standard quadruple therapy).There were 50 patients in each group.Statistical analysis of Helicobacter pylori eradication,remission of clinical symptoms,occurrence of adverse reactions and cost-effectiveness of the two groups.Results The radical cure rate was 94%in the study group and 88%in the control group,the difference was not statistically significant(P>0.05);The remission rate of clinical symptoms in the study group was 84%,Significantly higher than the 62%of the control group,The difference was statistically significant(P<0.05);The incidence of adverse reactions in the observation group was 12%,Significantly lower than the 54%of the control,The difference was statistically significant(P<0.05);The total cost of the study group was 143.02 yuan,and the total cost of the control group was 384.41 yuan,The cost of the study group was significantly lower than that of the control group.Conclusion The 7-day regimen containing Vonoprazan and amoxicillin can achieve the eradication rate of standard quadruple,the high remission rate of clinical symptoms,low adverse reactions,low cost,which is more worthy of promotion.